Chicago medical school launches stem cell biology centerBradenton HeraldA medical school in Chicago is launching a new center to study tissue regeneration and stem cell biology. The College of Medicine at the University of Illinois at Chicago says ther… Continue reading
Retraction Watch (blog) |
Weekend reads: A demand for a CRISPR paper retraction; a weak data-sharing policy; can we trust journals?
Retraction Watch (blog) Two companies whose stocks plummeted after a Nature Methods study claimed CRISPR introduced unexpected mutations want the study retracted because of alleged errors. (Antonio Regalado, Technology Review); “A policy with a couple of weak sticks and … |
|
‘Mismatch repair’ genetic defects drive cancer patient’s response to immunotherapy drugs
News-Medical.net In an expanded, three-year clinical trial of 86 patients with colorectal and 11 other kinds of cancer that have so-called ‘mismatch repair’ genetic defects, scientists at Johns Hopkins Medicine and its Bloomberg~Kimmel Institute for Cancer … |
FiercePharma |
Manufacturing costs loom large for personalized CAR–T cancer meds and their need for speed
FiercePharma Novartis, in explaining its new CAR-T cancer drug candidate, says T cells like this are drawn from a patient’s blood and reprogrammed in the laboratory so that they are genetically coded to hunt the patient’s cancer cells and other B cells expressing a … |
|
Bioventure AnGes MG tries again to market Japan’s first gene therapy
Nikkei Asian Review TOKYO — AnGes MG expects to apply in October for approval to manufacture and market a treatment for severe blockage of the arteries in the legs that could become the first commercial gene therapy product in Japan. The Japanese biopharmaceutical … |
PLoS Blogs (blog) |
Synthetic Biology: Step by Step Towards its Democratization
PLoS Blogs (blog) As an enthusiast and synthetic biology practitioner, what attracts me most of our field is how fast is spreading and how people from different domains start to ask questions and to get interested in what we do. In the past year, I’ve heard over and … |